ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences Statistics
Share Statistics
ReShape Lifesciences has 11.28M shares outstanding. The number of shares has increased by -85.91% in one year.
| Shares Outstanding | 11.28M |
| Shares Change (YoY) | -85.91% |
| Shares Change (QoQ) | 363.76% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 9.24M |
| Failed to Deliver (FTD) Shares | 17.5K |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 688.72K, so 20.84% of the outstanding shares have been sold short.
| Short Interest | 688.72K |
| Short % of Shares Out | 20.84% |
| Short % of Float | 21.11% |
| Short Ratio (days to cover) | 1.35 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is null. ReShape Lifesciences's PEG ratio is 0.
| PE Ratio | -0.32 |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | 0.3 |
| PB Ratio | -9.09 |
| P/FCF Ratio | -0.52 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ReShape Lifesciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of -3.82.
| Current Ratio | 0.92 |
| Quick Ratio | 0.43 |
| Debt / Equity | -3.82 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $470.94K |
| Profits Per Employee | $-419.41K |
| Employee Count | 17 |
| Asset Turnover | 1.67 |
| Inventory Turnover | 1.2 |
Taxes
| Income Tax | 39K |
| Effective Tax Rate | -0.55% |
Stock Price Statistics
The stock price has increased by -96.74% in the last 52 weeks. The beta is 1.93, so ReShape Lifesciences's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | -96.74% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 5.69 |
| Relative Strength Index (RSI) | 41.28 |
| Average Volume (20 Days) | 13.06M |
Income Statement
In the last 12 months, ReShape Lifesciences had revenue of 8.01M and earned -7.13M in profits. Earnings per share was -13.83.
| Revenue | 8.01M |
| Gross Profit | 5.06M |
| Operating Income | -6.67M |
| Net Income | -7.13M |
| EBITDA | -6.67M |
| EBIT | -6.67M |
| Earnings Per Share (EPS) | -13.83 |
Balance Sheet
The company has 693K in cash and 967K in debt, giving a net cash position of -274K.
| Cash & Cash Equivalents | 693K |
| Total Debt | 967K |
| Net Cash | -274K |
| Retained Earnings | -642.7M |
| Total Assets | 4.79M |
| Working Capital | -397K |
Cash Flow
In the last 12 months, operating cash flow was -4.43M and capital expenditures 0, giving a free cash flow of -4.43M.
| Operating Cash Flow | -4.43M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.43M |
| FCF Per Share | -8.59 |
Margins
Gross margin is 63.17%, with operating and profit margins of -83.29% and -89.06%.
| Gross Margin | 63.17% |
| Operating Margin | -83.29% |
| Pretax Margin | -88.57% |
| Profit Margin | -89.06% |
| EBITDA Margin | -83.29% |
| EBIT Margin | -83.29% |
| FCF Margin | -55.3% |
Dividends & Yields
RSLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for RSLS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 23, 2024. It was a backward split with a ratio of 1:58.
| Last Split Date | Sep 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:58 |
Scores
| Altman Z-Score | -190.22 |
| Piotroski F-Score | 2 |